Agree, it’s far far to cheap, we don’t need news, we know what they have. This will settle over 300p this week with no news. With news I just don’t know.
The real value is in the process and the ip rights though. Big pharmaceutical would love to have this capability in their arsenal. Bio techs always trade at crazy pe’s and takeovers in this sector always command big premiums. Health care is expensive.
Exactly. This is hard to put a valuation on but coronavirus is spreading rapidly. And this hit 250p without news before, will probably gonna beyond that.. with news who knows.
This is just a small holding for me but I added 1400 at 91p as thought they were taking the pee Friday and very glad I did just that.. it’s not even broken onto most people’s screens yet either... next week will see new highs I am sure. Just not sure how high this goes.. so difficult to put a value on it.
Agree this is a unique situation. Glaxo would probably pay 500m to add this to their vaccine and infectious disease arsenal and offer an all encompassing capability. Just part of q1 profit to them...
As long as you are not 70 plus, it’s lethal. Something like 20 percent get it severe and if that 20 percent another 20 percent die. Kids on the other hand may not even notice they have it. It really smacks the elderly hard.
88 posts in the last few hours on a Saturday, just shows the incredible level of interest here. They are clearly the leaders in this field and at 50m mkt cap the upside is considerable.